clinical_trials
Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism
Confidence95·multiple reportsImportance97NP-EVT-20261014-71BD859
Nature, Published online: 14 October 2026; doi:10.1038/s41586-026-11176-1 A tetravalent nanobody-based myeloid-selective IL-10 receptor agonist recapitulates IL-10’s potent suppression of monocytes, macrophages and dendritic cells while avoiding stimulation of T cells.
Read the original at the primary source
Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism
Tangsheng Yi · 10/14/2026, 12:00:00 AM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —